NED Talk: Novel Tx for RR MM

CE

How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Released: July 16, 2021

Expiration: July 15, 2022

Tiffany Richards
Tiffany Richards, PhD, ANP-BC, AOCNP

Activity

Progress
1
Course Completed
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.